LXRX Share Price | Lexicon Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Lexicon Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal supporting this view. The weekly MACD is also bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish trend in both weekly and monthly time frames. However, the KST shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment. In terms of performance, Lexicon Pharmaceuticals has delivered an impressive year-to-date return of 80.09%, significantly outperforming the S&P 500's 16.30% over the same period. However, over longer periods, such as 3 years, the stock has underperformed with a return of -37.85% compared to the S&P 500's 76.66%. Overall, the current technical indicators suggest a bullish stance, albeit with some mixed signals in the longer time frames.

Q: Is Lexicon Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 October 2023, Lexicon Pharmaceuticals, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, which indicate a solid financial position relative to its earnings and book value.When compared to peers, Amgen Inc. has a P/E ratio of 15.2, while Gilead Sciences, Inc. stands at a P/E of 11.8. This suggests that Lexicon Pharmaceuticals is trading at a discount relative to its industry peers, reinforcing the undervaluation narrative. Additionally, Lexicon's stock performance has outpaced the Sensex, further supporting the positive outlook on its valuation.

Q: What does Lexicon Pharmaceuticals, Inc. do?

Overview:Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for human disease, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.Financial Snapshot:Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) Market cap: USD 262.81 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.76 Return on Equity: -136.88% Price to Book: 2.14Contact Details:Address: 8800 Technology Forest Pl, THE WOODLANDS TX: 77381-1160 Tel: 1 281 8633000 Fax: 1 281 8638088

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

676.32 k

Shareholding (Jun 2026)

FII

37.44%

Held by 65 FIIs

DII

19.50%

Held by 56 DIIs

Promoter

47.86%

Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Lexicon Pharmaceuticals shows a bullish trend supported by strong daily moving averages and a year-to-date return of 80.09%, though it has underperformed over the past three years with a return of -37.85%.

View full answer

Is Lexicon Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Lexicon Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a D/E ratio of 0.3, indicating a solid financial position compared to peers like Amgen and Gilead, and its stock performance has outpaced the Sensex.

View full answer

What does Lexicon Pharmaceuticals, Inc. do?

22-Jun-2025

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for human diseases, with a market cap of approximately $262.81 million. As of March 2025, it reported net sales of $1 million and a net loss of $25 million.

View full answer

Who are in the management team of Lexicon Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Lexicon Pharmaceuticals, Inc. includes Mr. Lonnel Coats (CEO), Mr. Raymond Debbane (Chairman), and several independent directors: Mr. Philippe Amouyal, Dr. Samuel Barker, Dr. Robert Lefkowitz, Dr. Alan Nies, and Mr. Frank Palantoni. They oversee the company's strategic direction and operations.

View full answer

Compare Lexicon Pharmaceuticals, Inc. with Similar Stocks

Atea Pharmaceuticals, Inc.Ovid Therapeutics, Inc.Fulcrum Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared negative results in Jun 26 after 6 consecutive negative quarters

NET SALES(HY) At USD 21.79 MM has Grown at -27.66%
RAW MATERIAL COST(Y) Grown by 20% (YoY)
INVENTORY TURNOVER RATIO(HY) Lowest at 1.23 times

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 702 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.38

Return on Equity

-46.81%

Price to Book

6.52

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Jun 2026)

Net Profit:

-32 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.63%

6 Months

25.61%

1 Year

70.25%

2 Years

30.38%

3 Years

92.52%

4 Years

-11.59%

5 Years

-59.05%

Lexicon Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

15.72%

EBIT Growth (5y)

11.43%

EBIT to Interest (avg)

-30.95

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.13

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

69.85%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.52

EV to EBIT

-13.51

EV to EBITDA

-13.69

EV to Capital Employed

9.87

EV to Sales

13.27

PEG Ratio

Dividend Yield

ROCE (Latest)

-73.05%

ROE (Latest)

-46.81%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 25 Schemes (19.5%)

Foreign Institutions

Held by 65 Foreign Institutions (37.44%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -96.68% vs 283.64% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -3,080.00% vs 93.55% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "21.10",
          "chgp": "-96.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.40",
          "val2": "-0.90",
          "chgp": "-2,833.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "1.60",
          "chgp": "62.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.80",
          "val2": "-1.00",
          "chgp": "-3,080.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-38,352.60%",
          "val2": "-47.20%",
          "chgp": "-3,830.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 60.13% vs 2,491.67% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 74.90% vs -13.16% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.80",
          "val2": "31.10",
          "chgp": "60.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.30",
          "val2": "-184.30",
          "chgp": "73.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.30",
          "val2": "15.60",
          "chgp": "-46.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-12.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.30",
          "val2": "-200.40",
          "chgp": "74.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-982.10%",
          "val2": "-5,946.30%",
          "chgp": "496.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

0.70

21.10

-96.68%

Operating Profit (PBDIT) excl Other Income

-26.40

-0.90

-2,833.33%

Interest

2.60

1.60

62.50%

Exceptional Items

-4.30

0.00

Consolidate Net Profit

-31.80

-1.00

-3,080.00%

Operating Profit Margin (Excl OI)

-38,352.60%

-47.20%

-3,830.54%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is -96.68% vs 283.64% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is -3,080.00% vs 93.55% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

49.80

31.10

60.13%

Operating Profit (PBDIT) excl Other Income

-48.30

-184.30

73.79%

Interest

8.30

15.60

-46.79%

Exceptional Items

0.00

-12.30

100.00%

Consolidate Net Profit

-50.30

-200.40

74.90%

Operating Profit Margin (Excl OI)

-982.10%

-5,946.30%

496.42%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 60.13% vs 2,491.67% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 74.90% vs -13.16% in Dec 2024

All Annual Results

Company CV

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Company Coordinates

Company Details

8800 Technology Forest Pl , THE WOODLANDS TX : 77381-1160

Tel: 1 281 8633000

Registrar Details

Footer loading